# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target...
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...
Of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline. To date, d...
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...